Linked Life Data

21247767

Source:http://linkedlifedata.com/resource/pubmed/id/21247767

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21247767rdf:typepubmed:Citationlld:pubmed
pubmed-article:21247767lifeskim:mentionsumls-concept:C0028945lld:lifeskim
pubmed-article:21247767lifeskim:mentionsumls-concept:C1547647lld:lifeskim
pubmed-article:21247767lifeskim:mentionsumls-concept:C1521991lld:lifeskim
pubmed-article:21247767lifeskim:mentionsumls-concept:C0596545lld:lifeskim
pubmed-article:21247767lifeskim:mentionsumls-concept:C1521761lld:lifeskim
pubmed-article:21247767lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:21247767lifeskim:mentionsumls-concept:C0439234lld:lifeskim
pubmed-article:21247767lifeskim:mentionsumls-concept:C0205099lld:lifeskim
pubmed-article:21247767lifeskim:mentionsumls-concept:C0205171lld:lifeskim
pubmed-article:21247767pubmed:issue3lld:pubmed
pubmed-article:21247767pubmed:dateCreated2011-1-31lld:pubmed
pubmed-article:21247767pubmed:abstractTextThe increased chemosensitivity of oligodendroglial tumours has been associated with loss of heterozygosity (LOH) of the p arm of chromosome 1 and the q arm of chromosome 19 (LOH 1p/19q). Other clinical and molecular factors have also been identified as being prognostic and predictive of treatment outcome. We reviewed 105 patients with oligodendroglioma treated at a single centre over 20 years. Median survival in oligodendroglioma patients with LOH 1p/19q was significantly longer (10.9 vs. 2.0 years). In the anaplastic oligodendroglioma group, univariate analysis demonstrated decreased patient age, presentation with seizures, use of adjuvant chemotherapy and LOH 1p/19q as predictors of improved survival. Multivariate analysis confirmed LOH 1p/19q as a significant predictor of improved survival (hazard ratio, 3.4; p=0.015). Median survival in patients with anaplastic oligodendroglioma with LOH 1p/19q was 15.4 years vs. 1.2 years for those without LOH 1p/19q. This study confirms the utility of LOH 1p/19q as a prognostic marker in oligodendroglioma.lld:pubmed
pubmed-article:21247767pubmed:languageenglld:pubmed
pubmed-article:21247767pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21247767pubmed:citationSubsetIMlld:pubmed
pubmed-article:21247767pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21247767pubmed:statusMEDLINElld:pubmed
pubmed-article:21247767pubmed:monthMarlld:pubmed
pubmed-article:21247767pubmed:issn1532-2653lld:pubmed
pubmed-article:21247767pubmed:authorpubmed-author:LittleNichola...lld:pubmed
pubmed-article:21247767pubmed:authorpubmed-author:ParkinsonJona...lld:pubmed
pubmed-article:21247767pubmed:authorpubmed-author:BiggsMichael...lld:pubmed
pubmed-article:21247767pubmed:authorpubmed-author:CookRaymond...lld:pubmed
pubmed-article:21247767pubmed:authorpubmed-author:McDonaldKerri...lld:pubmed
pubmed-article:21247767pubmed:authorpubmed-author:PayneCathy...lld:pubmed
pubmed-article:21247767pubmed:authorpubmed-author:BrewerJanice...lld:pubmed
pubmed-article:21247767pubmed:authorpubmed-author:WheelerHelen...lld:pubmed
pubmed-article:21247767pubmed:authorpubmed-author:BucklandMicha...lld:pubmed
pubmed-article:21247767pubmed:authorpubmed-author:AfaghiVahidVlld:pubmed
pubmed-article:21247767pubmed:copyrightInfoCopyright © 2010 Elsevier Ltd. All rights reserved.lld:pubmed
pubmed-article:21247767pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21247767pubmed:volume18lld:pubmed
pubmed-article:21247767pubmed:ownerNLMlld:pubmed
pubmed-article:21247767pubmed:authorsCompleteYlld:pubmed
pubmed-article:21247767pubmed:pagination329-33lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:meshHeadingpubmed-meshheading:21247767...lld:pubmed
pubmed-article:21247767pubmed:year2011lld:pubmed
pubmed-article:21247767pubmed:articleTitleThe impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.lld:pubmed
pubmed-article:21247767pubmed:affiliationCerebral Tumour Research Laboratory, Hormones and Cancer Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Pacific Highway, St Leonards, New South Wales, Australia. jparkinson@med.usyd.edu.aulld:pubmed
pubmed-article:21247767pubmed:publicationTypeJournal Articlelld:pubmed